Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Chemoresistance is a major contributor to the aggressiveness of AML and is often due to insufficient apoptosis. The CFLAR gene is expressed as long and short splice forms encoding the anti-apoptotic proteins c-FLIP(L) and c-FLIP(S) (CFLAR(L) and CFLAR(S) , respectively) that play important roles in drug resistance. In univariate analyses of CFLAR mRNA expression in adult AML patients, those individuals with higher than median mRNA expression of the long splice form CFLAR(L) (but not the short splice form) had significantly lower 3 year overall survival (P = 0·04) compared to those with low expression. In cell line studies, simultaneous down-regulation of c-FLIP(L) and c-FLIP(S) proteins using siRNA induced apoptosis in U937 and NB-4 AML cells, but not K562 or OCI-AML3 cells. However, dual c-FLIP(L/S) downregulation sensitized all four cell lines to apoptosis induced by recombinant tumour necrosis factor-related apoptosis-inducing ligand (rTRAIL). Moreover, specific downregulation of c-FLIP(L) was found to recapitulate the phenotypic effects of dual c-FLIP(L/S) downregulation. The histone deacetylase (HDAC)1/2/3/6 inhibitor Vorinostat was found to potently down-regulate c-FLIP(L) expression by transcriptional and post-transcriptional mechanisms and to sensitize AML cells to rTRAIL. Further analyses using more selective HDAC inhibitors revealed that HDAC6 inhibition was not required for c-FLIP(L) down-regulation. These results suggest that c-FLIP(L) may have clinical relevance both as a prognostic biomarker and potential therapeutic target for HDAC inhibitors in AML although this requires further study.

Original publication

DOI

10.1111/bjh.12108

Type

Journal article

Journal

Br J Haematol

Publication Date

01/2013

Volume

160

Pages

188 - 198

Keywords

Adolescent, Adult, Aged, Alternative Splicing, Apoptosis, CASP8 and FADD-Like Apoptosis Regulating Protein, Cell Line, Tumor, Down-Regulation, Drug Resistance, Neoplasm, Female, Gene Expression Regulation, Leukemic, Histone Deacetylase 6, Histone Deacetylase Inhibitors, Histone Deacetylases, Humans, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute, Male, Middle Aged, Neoplasm Proteins, Prognosis, RNA Interference, RNA, Messenger, RNA, Neoplasm, RNA, Small Interfering, Recombinant Proteins, TNF-Related Apoptosis-Inducing Ligand, Young Adult